Track market-moving stories before they get noisy

On June 01, 2026, Booz Allen Hamilton Holding Corp BAH shares rose 6.2% to a current price of $84.05. This price is situated within a 52-week range of $68.84 to $120.05, reflecting notable volatility over the past year.

GF Value™ verdict: The current price is $84.05, which is 39.9% below the GF Value™ estimate of $139.80.GF Score™: 76/100, indicating an above-average potential for long-term returns.Most notable signal: There have been no insider transactions in the last 3 months. Is BAH Overvalued or Undervalued? With a current price of $84.05 compared to a GF Value™ of $139.80, Booz Allen Hamilton Holding Corp BAH appears to be significantly undervalued, presenting a margin of safety of approximately 39.9%. The GF Valuation label indicates that the stock is significantly undervalued, which suggests that there is substantial upside potential if the market corrects itself toward the intrinsic value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

However, while the undervaluation presents an opportunity, it is important to consider potential risks associated with the company’s recent performance. The stock has experienced a decline of 18.9% over the past year, indicating it may be facing challenges that could affect its recovery and the realization of its intrinsic value.

How Does BAH's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 12.2x 23.9x Forward P/E 13.4x N/A BAH's current P/E (TTM) of 12.2x is significantly below its 5-year median P/E of 23.9x, indicating that the stock is trading at a substantial discount relative to its historical valuation. This analysis aligns with the GF Value™ verdict, reinforcing the notion that the stock is undervalued and may present a buying opportunity for investors who are willing to navigate the associated risks.

What Does BAH's GF Score™ Tell Us? Metric Rating GF Score™ 76 Financial Strength 5/10 Profitability 9/10 Growth 9/10 Valuation 4/10 Momentum 1/10 The GF Score™ of 76/100 indicates that Booz Allen Hamilton Holding Corp BAH has a strong potential for long-term returns, particularly highlighted by its high profitability rank (9/10) and growth rank (9/10). However, it shows weakness in momentum (1/10) and valuation (4/10), suggesting that while the fundamentals are solid, the stock may not be experiencing favorable market trends at this time.

What Are Insiders Doing with BAH Stock? In the last three months, there have been no insider transactions reported for Booz Allen Hamilton Holding Corp BAH . This lack of activity may suggest that insiders are not currently taking positions in the stock, which could indicate either a lack of confidence in the near-term prospects or a wait-and-see approach amidst market fluctuations.

What This Means for Investors Based on the GF Value™ assessment, Booz Allen Hamilton Holding Corp BAH appears to be undervalued at its current price of $84.05, suggesting a significant opportunity for investors who can withstand potential volatility. However, it’s crucial for potential investors to consider the recent performance trends and the lack of insider activity before making any decisions.

For the complete analysis, visit the Booz Allen Hamilton Holding Corp BAH stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is BAH's GF Score™?

BAH's GF Score™ is 76/100, indicating an above-average potential for long-term returns based on key financial metrics.

Is BAH overvalued or undervalued?

BAH is undervalued according to the GF Value™ estimate, with a current price of $84.05 being 39.9% below its intrinsic value of $139.80.

What is BAH's P/E ratio?

The P/E ratio for BAH is currently 12.2x, which is significantly below its 5-year median P/E of 23.9x, indicating that the stock is trading at a discount compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

First head-to-head analysis finds Chinese LLMs produced and obfuscated vulnerable code for U.S. applications

MCLEAN, Va.--(BUSINESS WIRE)--Booz Allen has released a new report, What's In America's Code?, examining the national security implications of popular Chinese large language models (LLMs) used in software development and security workflows. Using its AI-native testing platform, Booz Allen evaluated four Chinese frontier models and one American model to assess code quality, security, and model behavior.

Following comparative testing and scenario-driven analysis across more than 2,800 trials and nearly 450,000 lines of code, the research revealed that three of four Chinese models produced significantly more vulnerable code when prompted with a U.S. government persona, and the vulnerabilities were highly obfuscated.

Key takeaways and recommendations from the report include:

Chinese LLMs generated more vulnerable code for U.S. government users. The models produced less secure code overall, with vulnerabilities increasing when prompted by users identifying as members of the U.S. government. Chinese LLMs exhibited PRC-aligned political bias. The models refused certain politically sensitive requests and incorporated China-aligned perspectives into generated outputs. Ban untrusted AI models from government and critical infrastructure environments. Models that cannot demonstrate trustworthy and reliable behavior should not be used in systems supporting national security or critical functions. Invest To Make Trusted American AI Models the Global Default. To drive adoption, American AI companies must collaborate with the U.S. government to ensure American models are both commercially compelling and economically viable. The findings raise concerns about the growing access and use of foreign-developed AI models across software supply chains supporting critical infrastructure and national security missions that security processes cannot detect. Read the full report.

About Booz Allen Hamilton

Booz Allen is an advanced technology company delivering outcomes with speed for America’s most critical defense, civil, and national security priorities. We build technology solutions using AI, cyber, and other cutting-edge technologies to advance and protect the nation and its citizens. By focusing on outcomes, we enable our people, clients, and their missions to succeed—accelerating the nation to realize our purpose: Empower People to Change the World®.

With global headquarters in McLean, Virginia, our firm employs approximately 31,500 people globally as of March 31, 2026, and had revenue of $11.2 billion for the 12 months ended March 31, 2026. To learn more, visit www.boozallen.com. (NYSE: BAH)

BAHPR-CO

Have you ever heard of Succession Risk? It occurs when key leaders of a company leave their position—whether expected or not—and a clear successor isn’t already in place.

When key leaders leave, there is a loss of both knowledge and experience that can be hard to replace. And there is always a lag getting someone new up to speed, even though that can be minimized with an internal promotion.

It often creates uncertainty among shareholders that ends up being priced into shares.

That’s exactly what happened to The Clorox Company (CLX) last week. Chairman and Chief Executive Officer Linda Rendle decided to step down for health reasons. The plan is for her to remain in office while a search is conducted and then through a period where she will act as an advisor.

The stock was already struggling, and CLX shares slid another 6% on Friday on the news.

Now, I still like CLX as a long-term holding, and I think some new blood in the C-suite could be a good thing. But still, markets are clearly trying to quantify the risks during this succession period and price it into the shares.

Personally, I will grab a few more shares at an even lower price.

This is another example of “hidden risks” that can sneak into your portfolio. On the surface, they can spook investors and erase your gains, even if just temporarily. On a deeper level, they can disrupt a company’s operations, negatively impact earnings, and cause our dividend payments to become vulnerable.

Let’s take a look at other risks.

Some Risks Can Be Measured It is hard to put a specific dollar amount on the succession risk for Clorox (despite the market trying anyway). But there are risks that can be measured.

One is key customer concentration risk. This becomes an issue when a few customers—or maybe even a single customer—make up a large share of a company’s revenue. This also applies if your customers are concentrated in a specific industry or geographic location.

An example in the news is Booz Allen Hamilton Holding Corp. (BAH). Roughly 98% of its revenue comes from government contracts, and dozens of them were cancelled over the past year. This included 31 contracts with the Treasury Department cancelled in January. Shares are down 20% over the past year while the overall market is at all-time highs.

We can put into numbers the revenue that would be lost if a specific customer or contract falls off the balance sheet.

Another risk that’s incredibly relevant right now is refinancing risk. This occurs when a company has debt maturing that must be refinanced. Debt issued at low interest rates during 2020-2021 may end up being replaced by debt at much higher interest rates. That raises finance costs and can eat into free cash flow and possibly into our dividends.

Lastly, there’s currency risk. As a dividend investor who looks for long-term holdings, I always hold some global consumer staples giants.

These companies earn revenue in multiple currencies that must be converted into their reporting currency. Changes in exchanges rates can impact both earnings and forward guidance numbers. This is another thing to consider when investing in foreign companies.

Analysts are continually running the numbers to estimate the impact these risks will have on future earnings and dividend health. Some risks, however, require a more creative approach.

And Other Risks, Not So Much Potential hazards such as regulatory risk and litigation risk are much harder to measure. Instead of the spread between interest rates or the percentage of revenues, we are talking about complex probability models.

Both of these risks can severely impact a company’s future profits and be largely beyond its control. I always have pharmaceutical and tobacco companies in my portfolio. They both rely heavily on the decisions of regulators, specifically the FDA.

Pfizer (PFE) needs approvals on new drugs in its pipeline to offset patent cliffs. And Philip Morris (PM) still sells its outdated IQOS heated tobacco device here in the US because it’s waiting on approval for its new model.

Litigation risks are even harder to measure as they can pop up out of nowhere.

That brings me to the most top-of-mind risk—technology disruption risk. These days, it might be more accurate to call it AI adoption risk. This concern ripped through software stocks in the first quarter and is far from over.

I’m still not convinced that AI is ready to take on most tasks today… or in the near term. But it will for sure change the future of many companies, industries, and professions. And analysts are trying to measure the risk.

None of these risks should be instant deal breakers when screening for stocks to add to your portfolio, but you want to recognize when they are present. For some stocks, you might be able to use temporary risk speculation to lock in an even better price, and in turn a higher yield.

Do you consider these risks when you add new positions to your portfolio? What other hidden risks are you watching for in the current economy?

For more income, now and in the future,

Kelly Green

Originally published June 3, 2026

For more news, information, and strategy, visit ETF Trends.

Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target

May 26, 2026 19:18 ET  | Source: Bright Minds Biosciences

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:

DATE:Wednesday, June 3, 2026TIME:4:20PM EDTWEBCAST:Click Here   The live and archived webcast will be accessible from the Company’s website at https://investors.brightmindsbio.com/news-events/presentations under Events and Presentation. The replay of the webcast will be accessible for 30 days.

Bright Minds further releases that the Company has granted stock options (the “Options”) to certain directors, officers and consultants of the Company to purchase an aggregate of 109,000 common shares in the capital of the Company (the “Shares”) pursuant to the Company's share option plan. The Options are exercisable at a price of US$83.40 per Share for a period of five (5) years from the date of grant. The Options vest in four (4) equal annual instalments of 25% each, commencing on the first anniversary of the date of grant.

About Bright Minds Biosciences

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: [email protected]

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: [email protected]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - May 31, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the study design for the Company's Phase 3 PROSERA study, particularly, controlling for the placebo response at the Latin American testing sites.

On February 23, 2026, Gossamer Bio, Inc. revealed adverse topline results from its Phase 3 PROSERA study, announcing that the trial failed to meet its primary endpoint of improving six-minute walk distance ("6MWD") at Week 24. While the study reported a placebo-adjusted gain of +13.3 meters, the result did not achieve statistical significance under the prespecified alpha threshold of 0.025 (p=0.0320). The Company attributed the outcome, in part, to unexpectedly strong placebo performance among patients enrolled at Latin American sites, which it characterized as a heavily treated, lower-risk population.

Following this disclosure, investors and analysts reacted swiftly and negatively. On February 23, 2026, Gossamer's common stock price plummeted from a closing price of $2.13 per share on February 20, 2026 to $0.42 per share, representing a decline of more than 80% in a single trading day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Gossamer's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Gossamer Bio class action, go to www.faruqilaw.com/GOSS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299429

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SAN FRANCISCO, May 31, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026.

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of GOSS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: June 16, 2025 to February 20, 2026
DEADLINE: June 1, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Gossamer misled investors by concealing facts about issues with its Phase 3 PROSERA study. Based on these facts, Gossamer's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

, /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026.

The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24). The study evaluated seralutinib for the treatment of pulmonary arterial hypertension ("PAH").

The developments, including the trial failure and 80% stock drop, prompted national shareholder rights firm Hagens Berman to commence an investigation into the alleged pending claims that Gossamer violated federal securities laws.  The firm encourages Gossamer investors who suffered substantial losses on Class Period GOSS investments to submit your losses now.

The firm also encourages persons with knowledge who may be able to assist the investigation to contact its attorneys.

View our latest video summary of the allegations: youtu.be/TOr_OsDdBXY

Class Period: June 16, 2025 – Feb. 20, 2026
Lead Plaintiff Deadline: June 1, 2026
Visit: www.hbsslaw.com/investor-fraud/goss
Contact the Firm Now: [email protected]
                                        844-916-0895

Gossamer Bio, Inc. (GOSS) Securities Class Action:

The litigation is focused on the propriety of Gossamer's disclosures about the Phase 3 PROSERA trial design, including its patient recruitment protocol and site-level monitoring.

In the past, Gossamer has emphasized that serlutinib is a "potential first-in-class therapeutic[,]" which "represents the possibility of a multi-billion-dollar opportunity across multiple indications[.]"

As recently as mid-November 2025, the company's management cited the highly successful Merck Phase 3 STELLAR study of sotatercept for treating PAH. Gossamer's management said, "if you look at their data, the best performing region was Latin America, and we have actually more patients coming from those same geographies and same sites." Management also assured investors that "we have gone to the places where precedent studies have shown the greatest amount of efficacy, as well as having an entry criteria that is ensuring that we have patients who, we believe, will really show an improvement based upon, again background disease at week 24."

The complaint alleges that, unknown to investors, Gossamer knew of or recklessly disregarded the trial design issues with the Phase 3 PROSERA study and, instead, crafted a narrative assuring investors that it would meet its primary endpoint. Also unknown to investors, patients at the study's Latin America sites were largely heavily-treated and performing particularly well on placebo.

Investors' expectations were dashed on February 23, 2026. That day, Gossamer announced that PROSERA did not meet its primary endpoint and therefore efficacy was not statistically significant.

Management said during the conference call that day, "[t]he overall treatment effect and statistical parameters were materially diluted by an outsize placebo response and meaningful regional heterogeneity, which compressed the pool placebo-adjusted difference." More specifically, management revealed that in "Latin America, outsized placebo improvements materially compressed the pool treatment difference."

The market swiftly reacted, sending the price of Gossamer shares down by 80%.

After the Class Period, on April 9, 2026, the company revealed that since February 24, 2026 it has not met the minimum share bid price ($1) required for continued listing on the Nasdaq Global Select Market.

"We're focused on whether Gossamer may have misled investors about the PROSERA trial design, including patient entry criteria, as alleged in the pending lawsuit," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Gossamer Bio and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now.

If you'd like more information and answers to additional frequently asked questions about the Gossamer case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Gossamer Bio should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

SOURCE Hagens Berman Sobol Shapiro LLP

LOS ANGELES, June 01, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Gossamer Bio, Inc. (NASDAQ: GOSS)
Class Period: June 16, 2025 – February 20, 2026
Lead Plaintiff Deadline: June 1, 2026

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) patients at the Latin American sites were largely heavily-treated and lower risk and, ultimately, performed particularly well on the placebo, thus, Gossamer’s Phase 3 PROSERA study failed to meet the primary endpoint of improved six-minute walk distance at week 24; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are a Gossamer shareholder who suffered a loss, click here to participate.

New Era Energy & Digital, Inc. (NASDAQ: NUAI)
Class Period: November 6, 2024 – December 29, 2025
Lead Plaintiff Deadline: June 1, 2026

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) the Company overstated its progress in its permitting and regulatory filings for its flagship Texas Critical Data Centers project; (2) the Company was involved in a fraudulent scheme “to pocket revenues from hundreds of oil and gas wells in New Mexico” by transferring wells among related entities and then placing liability-bearing companies into bankruptcy to avoid plugging and remediation costs; (3) that, as a result, the Company’s financial results were false and/or misleading; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you are a New Era shareholder who suffered a loss, click here to participate.

Medpace Holdings, Inc. (NASDAQ: MEDP)
Class Period: April 22, 2025 – February 9, 2026
Lead Plaintiff Deadline: June 5, 2026

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants: (1) consistently oversold the Company’s projected book-to-bill ratio for fourth quarter 2025; (2) knew or recklessly disregarded the impact that cancellations have on the Company’s book-to-bill ratio; (3) frequently claimed that the projection of a 1.15 book-to-bill ratio for fourth quarter 2025 was reasonable and achievable and that cancellations were not a sign of a weak business environment; (4) reassured investors that the Company was not concerned about the lack of diversity in its pre-backlog; (5) stated that, despite the uptick in metabolic growth, the Company’s upside was broad-based and not isolated to any handful of studies; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you are a Medpace shareholder who suffered a loss, click here to participate.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”), are encouraged to contact the firm before June 1, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Gossamer concealed adverse facts about the design of its Phase 3 PROSERA study, especially regarding controls for placebo response at certain testing sites. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Gossamer, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601367847/en/

New York, New York--(Newsfile Corp. - June 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/GOSS.

Gossamer Case Details

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:

while publicly touting overwhelmingly positive results to investors, Defendants concealed material adverse facts regarding the design of the Company's Phase 3 PROSERA study, including their failure to adequately control for placebo response at the Latin American testing sites; and as a result of the foregoing, Gossamer's securities traded at artificially inflated prices, causing Plaintiff and other Class members to purchase shares at inflated levels.What's Next for Gossamer Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/GOSS, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Gossamer you have until June 1, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Gossamer Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Gossamer Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294910

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) and reminds investors of the June 1, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601532429/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the study design for the Company’s Phase 3 PROSERA study, particularly, controlling for the placebo response at the Latin American testing sites.

On February 23, 2026, Gossamer Bio, Inc. revealed adverse topline results from its Phase 3 PROSERA study, announcing that the trial failed to meet its primary endpoint of improving six-minute walk distance (“6MWD”) at Week 24. While the study reported a placebo-adjusted gain of +13.3 meters, the result did not achieve statistical significance under the prespecified alpha threshold of 0.025 (p=0.0320). The Company attributed the outcome, in part, to unexpectedly strong placebo performance among patients enrolled at Latin American sites, which it characterized as a heavily treated, lower-risk population.

Following this disclosure, investors and analysts reacted swiftly and negatively. On February 23, 2026, Gossamer’s common stock price plummeted from a closing price of $2.13 per share on February 20, 2026 to $0.42 per share, representing a decline of more than 80% in a single trading day.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Gossamer’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Gossamer Bio class action, go to www.faruqilaw.com/GOSS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601532429/en/

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the “Exchange Offer”) to exchange any and all of its 5.00% Convertible Senior Notes due 202.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sezzle Inc. ("Sezzle" or the "Company") (NASDAQ: SEZL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Sezzle and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 9, 2026, Sezzle disclosed in a filing with the U.S. Securities and Exchange Commission that it had "received a letter from Karen Webster", who served on the Company's Audit and Risk Committee, Compensation Committee, and Nominating and Corporate Governance Committee, stating that "she resigned from her position as a member of the Company's Board of Directors (the 'Board'), effective immediately." According to Sezzle, "Ms. Webster stated in her letter that her resignation resulted from a growing difference in perspective with management concerning the Company's direction, key decisions, and governance." 

On this news, Sezzle's stock price fell $9.41 per share, or 13.61%, to close at $59.71 per share on April 10, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

Sezzle (SEZL) stands out as a compelling BNPL investment among recent IPOs in the sector. Modern BNPL players like AFRM and Afterpay have solved legacy financing challenges, fueling sector growth. SEZL's positioning leverages advancements in BNPL infrastructure and addresses retailer pain points.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of Sezzle Inc. (“Sezzle” or the “Company”) (NASDAQ: SEZL) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE AN SEZZLE INC. (SEZL) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE.Contact Us To Participate or Learn More:If you still hold Sezzle shares purchased before December 2024 and wish to discuss.

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sezzle Inc. (“Sezzle” or the “Company”) (NASDAQ: SEZL).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Sezzle and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 9, 2026, Sezzle disclosed in a filing with the U.S. Securities and Exchange Commission that it had “received a letter from Karen Webster”, who served on the Company’s Audit and Risk Committee, Compensation Committee, and Nominating and Corporate Governance Committee, stating that “she resigned from her position as a member of the Company’s Board of Directors (the ‘Board’), effective immediately.”  According to Sezzle, “Ms. Webster stated in her letter that her resignation resulted from a growing difference in perspective with management concerning the Company’s direction, key decisions, and governance.” 

On this news, Sezzle’s stock price fell $9.41 per share, or 13.61%, to close at $59.71 per share on April 10, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

LOS ANGELES, May 19, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sezzle Inc. (“Sezzle” or “the Company”) (NASDAQ: SEZL) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sezzle revealed in an SEC filing on April 9, 2026, that it had received correspondence from Karen Webster, a member of its Board of Directors who served on its Audit and Risk Committee, Compensation Committee, and Nominating and Corporate Governance Committee. According to the Company, Weber stated that "she resigned from her position as a member of the Company's Board of Directors (the ‘Board'), effective immediately." The Company added, "Ms. Webster stated in her letter that her resignation resulted from a growing difference in perspective with management concerning the Company's direction, key decisions, and governance." Based on this news, shares of Sezzle fell by more than 13.6% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm 
Brian Schall, Esq. 
310-301-3335
[email protected]
www.schallfirm.com

-

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of Sezzle Inc. (“Sezzle” or the “Company”) (NASDAQ: SEZL) whether the board breached its fiduciary duties to shareholders.

IF YOU ARE AN SEZZLE INC. (SEZL) SHAREHOLDER, CLICK HERE TO PARTICIPATE.

Contact Us To Participate or Learn More:

If you still hold Sezzle shares purchased before December 2024 and wish to discuss this matter with us, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.

Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice

Persons with non-public information regarding Sezzle should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP

GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm’s recent successes, GPWR was named one of Law360’s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Glancy Prongay Wolke & Rotter LLP

Back to Newsroom

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a top complex litigation law firm, is investigating Sezzle Inc. (NASDAQ: SEZL) (“Sezzle” or the “Company”) for potential violations of the federal securities laws.

On April 9, 2026, Sezzle disclosed in a filing with the U.S. Securities and Exchange Commission that it had “received a letter from Karen Webster,” who served on the Company’s Audit and Risk Committee, Compensation Committee, and Nominating and Corporate Governance Committee, stating that “she resigned from her position as a member of the Company’s Board of Directors (the ‘Board’), effective immediately.” According to Sezzle, “Ms. Webster stated in her letter that her resignation resulted from a growing difference in perspective with management concerning the Company's direction, key decisions, and governance.”

“Our investigation concerns whether the company and its executives provided investors with accurate and complete information about the company,” said attorney Andrea Farah, Lowey Dannenberg, P.C. partner and head of the firm’s securities practice.

If you suffered a loss of more than $50,000 in SEZL securities, and wish to participate, or learn more about your eligibility, contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256 
Email:  [email protected] 

SOURCE: Lowey Dannenberg

Key Takeaways DAVE's Q1 2026 new members rise 22% to 695K. Revenues rise 47% and adjusted EBITDA soars 57%.SEZL's Q1 GMV rises 37.3%. Revenues increase 29.2% (12.2% of GMV) with MODS up 34.8%.DAVE ExtraCash originations gained 7% y/y, while CashAI v5.5 helped push 28-day DPD to 1.69%. Dave (DAVE - Free Report) and Sezzle (SEZL - Free Report) are fintech companies that target consumer-oriented payments and provide banking alternatives. While DAVE focuses on cash advances, SEZL offers interest-free installment plans at online stores.

Let us delve deeper to find out which of these two stocks investors should add to their portfolios.

The Case for DAVEDave’s growth is grounded in its customer-first strategy, whereby membership expansion contributes to the company’s solid financial performance. During the first quarter of 2026, the company witnessed 22% year-over-year growth in its new members to 695,000, with monthly transacting members gaining 18% year over year. Despite this sharp growth in customer base, the company managed to keep the customer acquisition cost flat year over year at $18 flat.

The company’s customer base expansion drove its first-quarter top line by 47% year over year. This impressive growth drove the company’s adjusted EBITDA by 57% year over year. Furthermore, the bottom line gained 64% year over year. Overall, the company displayed substantial operational efficiency and profitability.

With an upsurge in customer activity, ExtraCash originations surged 37% year over year. While this solid growth increased the inherent risk of credit default, the company’s proprietary AI and machine-learning-based CashAI v5.5 catered to the heightened risk. During the first quarter of 2026, Dave’s 28-day past-due (DPD) rate dipped to a record low of 1.69% from 1.7% reported in the year-ago quarter. Subsequently, the company’s net monetization rate was at 5.1%, marking the highest level achieved over the past four years.

On the liquidity front, Dave appears to hold a solid position. The company ended the first quarter of 2026 with $176 million in cash against current debt of $75 million. Furthermore, its current ratio of 3.86 surpassed the industry average of 1.57. A current ratio of more than bodes well with investors as it signals efficiency in paying short-term obligations.

The Case for SEZLDuring the first quarter of 2026, Sezzle recorded remarkable growth of 37.3% year over year in its gross merchandise volume (GMV). This lofty growth led to a solid 29.2% year-over-year upsurge in the top line, which represented 12.2% of GMV. The top-line growth can also be attributed to a 34.8% year-over-year gain in Monthly On-Demand & Subscribers (MODS).

Sezzle’s noteworthy performance is fueled by the company’s customer-centric strategy that successfully boosted customer engagement. An improvement in average purchase frequency to 7.1X from the year-ago quarter’s 6.1X reflects the company’s solid customer engagement strategy. It demonstrates that customers do not use SEZL for one-off transactions, but rather utilize it for daily spending habits.

SEZL’s marketing expense more than doubled from the year-ago quarter. While this could have affected profitability, it improved operating income by 38.4% year over year. It highlights that the company’s ability to draw in customers is tied to its vigorous marketing spend without compromising scalability and efficiency. It led to a 48.4% year-over-year upsurge in active subscribers.

The company’s liquidity profile is a standout. As of the end of March 31, 2026, SEZL held cash amounting to $125 million with no current debt. Strength in its liquidity position is further evidenced by its current ratio of 3.65, an improvement from the preceding quarter’s 2.62. Furthermore, the metric exceeds the industry average of 1.1. That said, Sezzle’s current ratio is greater than 1, which is a green flag for investors as it signals efficiency in fulfilling short-term obligations.

How Do Estimates Compare for DAVE & SEZL?The Zacks Consensus Estimate for Dave’s 2026 revenues is $713.7 million, indicating an upside of 28.8% year over year. For 2026, the consensus mark for earnings is pegged at $15.46 per share, suggesting a 17.3% upsurge from the year-ago quarter’s actual. Over the past 60 days, three estimates for 2026 have shifted upward, with no downward revisions.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Sezzle’s 2026 sales is pinned at $592.6 million, implying a 31.6% year-over-year increase. The consensus estimate for earnings is pegged at $5.09 per share, suggesting a 41.8% jump from the year-ago quarter’s actual. Four estimates for 2026 have moved north in the past 60 days versus no southward revisions.

Image Source: Zacks Investment Research

DAVE Trades Cheaper Than SEZLSezzle is currently trading at a forward 12-month price/earnings (P/E) ratio of 18.46, which is higher than the 12-month median of 17.24. Dave trades at a 12-month P/E ratio of 13.41, which is below the 12-month median of 21.29. This comparison highlights the fact that Dave is undervalued compared to Sezzle.

Image Source: Zacks Investment Research

Verdict: DAVE is a Better BuyBoth Dave and Sezzle are outstanding stocks to add to your portfolio. However, Dave appears to be a better buy due to its superior financial growth and undervaluation. During the first quarter of 2026, DAVE outperformed SEZL with solid 47% year-over-year growth in its top line, fueled by a 22% year-over-year rise in members.

While the company experienced swift scaling, it maintained a customer acquisition cost of $18 and leveraged CashAI v5.5 to manage credit risk, resulting in a dip in its 28 DPD rate to a record low. Furthermore, Dave’s current ratio stands at 3.86, hinting at a stellar liquidity position. Notably, Dave trades at a cheaper price than SEZL, making it an undervalued gem and providing investors with a high-growth opportunity as the market realizes the stock’s true potential.

SEZL and DAVE sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

On May 27, 2026, Sezzle Inc SEZL shares rose 5.5% to a current price of $116.05. This recent uptick comes amidst a 52-week range that has seen the stock fluctuate between $49.50 and $186.74.

GF Value™ verdict: Current price of $116.05 is 63.9% above the GF Value™ estimate of $70.81.GF Score™: 67/100, indicating above-average performance based on GuruFocus metrics.Notable signal: Insiders sold $5.4M in shares over the last three months, with no reported purchases. Is SEZL Overvalued or Undervalued? The current price of Sezzle Inc SEZL at $116.05 is significantly above its GF Value™ estimate of $70.81, reflecting a 63.9% overvaluation. This discrepancy indicates a lack of margin of safety for potential investors, as the market price does not align with the intrinsic value calculated by GuruFocus. The GF Valuation label categorizes SEZL as "Significantly Overvalued," which raises concerns for those considering a position in the stock.

If the stock remains overvalued, there is an inherent risk of a price correction, which could negatively impact returns for those entering at current levels. Conversely, if the stock trades down towards its GF Value™, it could create a more compelling investment opportunity in the future. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

How Does SEZL's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 27.8x 21.8x Forward P/E 22.6x N/A Sezzle's current P/E ratio of 27.8x is notably higher than its 5-year median P/E of 21.8x, representing a 27% premium. This analysis suggests that SEZL is trading above its historical valuation levels, which aligns with the GF Value™ verdict of being overvalued. The elevated P/E ratio indicates that investors may be paying a premium for earnings compared to historical standards.

What Does SEZL's GF Score™ Tell Us? Metric Rating GF Score™ 67 Financial Strength 6/10 Profitability 4/10 Growth 5/10 Valuation 3/10 Momentum 7/10 The GF Score™ of 67/100 indicates a relatively strong overall performance, particularly in momentum, where the stock ranks 7/10. However, the valuation aspect scores the lowest at 3/10, reinforcing the notion that the stock is overvalued. Financial strength is rated 6/10, suggesting a moderate level of stability, while profitability and growth rank lower at 4/10 and 5/10 respectively, indicating areas for improvement.

What Are Insiders Doing with SEZL Stock? In the past three months, insider activity has seen a significant amount of selling, totaling $5.4 million, with no recorded purchases. This trend might suggest a lack of confidence from insiders regarding the stock's future performance, further indicating potential concerns about its current valuation.

What This Means for Investors Based on the current GF Value™ estimate, Sezzle Inc SEZL is classified as overvalued. The significant premium over the GF Value™ suggests caution for prospective investors, as the stock may face downward pressure in alignment with its intrinsic value.

For the complete analysis, visit the Sezzle Inc SEZL stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is SEZL's GF Score™?

SEZL has a GF Score™ of 67, indicating above-average performance based on key financial metrics.

Is SEZL overvalued or undervalued?

SEZL is currently overvalued, with a significant premium over its GF Value™ estimate of $70.81.

What is SEZL's P/E ratio?

SEZL's P/E (TTM) is 27.8x, which is 27% above its 5-year median P/E of 21.8x, indicating a higher valuation compared to its historical levels.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Conference call expected to provide additional details on the Company's path to cash-flow positivity and key operational milestones. WEST SENECA, NY / ACCESS Newswire / March 11, 2026 / Worksport Ltd.

Thursday, 26 March 2026 04:00 PM

Topic: 

Company Update Revenue Increases 90% YoY; Company Highlights Margin Expansion and Commercialization Milestones

WEST SENECA, NY / ACCESS Newswire / March 26, 2026 / Worksport Ltd. (NASDAQ:WKSP) ("Worksport" or the "Company"), a U.S.-based innovator and manufacturer of hybrid and clean energy solutions primarily for the light truck, overlanding, and global consumer goods markets, today announced financial results for the full year ended December 31, 2025, as filed in its Annual Report on Form 10-K.

Fiscal 2025 Highlights

Record Net Sales: Net sales for fiscal 2025 reached $16.1 million, an 89.8% increase compared to $8.5 million in fiscal 2024.

Significant Margin Expansion: Full-year gross margin improved to 28%, up from 11% in fiscal 2024.

Strong Q4 Performance: Derived fourth-quarter gross margins reached approximately 30%, reflecting increased manufacturing efficiency and capacity utilization at the Company's New York facility.

Dealer Network Growth: The partnered dealer network expanded sixfold in 2025, now exceeding 550 locations across the U.S. and Canada.

Online Sales Growth: Online sales grew 142% to $11.9 million, representing 74% of total revenue

Business-to-Business Growth: Distributor and jobber sales increased to $4.2 million, up from $0.4 million in 2024

Commercial Product Launches: Successfully launched the SOLIS solar-integrated cover and COR portable energy storage system in December 2025.

Quality Certification: Achieved ISO 9001 certification in April 2025, a critical prerequisite for pursuing Tier-1 OEM relationships with major automotive manufacturers.

Management noted that 2025 marked a transition year, with multiple product lines moving from development into early-stage commercialization.

2026 Financial Guidance and Strategic Outlook

Following a year of foundational investment, Worksport is providing the following guidance for fiscal 2026:

Revenue Guidance: The Company expects full-year 2026 revenue to be between $35 million and $42 million.

Gross Margin Target: Management has set a stable target of 35% gross margin for fiscal 2026.

Network Expansion: Management targets aggressive dealer network growth to 1,500 locations by the end of 2026. This dealer expansion is expected to be a leading revenue driver.

Path to Profitability: Worksport expects to reach initial operational cash-flow positivity within the second half of 2026.

"Game Changer" Product Launch: A next-generation hard tonneau cover featuring patented capabilities is expected to launch in early Q2 2026.

Balance Sheet and Liquidity

As of December 31, 2025, Worksport reported:

$5.95 million in cash

$3.4 million available under its revolving credit facility

Total liquidity of approximately $9.3 million

The Company indicated that its capital deployment in 2025 was directed toward scaling production capacity and advancing commercialization efforts.

Management Commentary

"2025 was a transformative year where we successfully bridged the gap from product conceptualization to large-scale market delivery," said Steven Rossi, Worksport Founder & CEO. "We nearly doubled our top-line growth while dramatically improving our margin profile. With our New York facility now capable of producing over 125 units per 8-hour shift and our R&D hub in Missouri de-risking our clean-energy product launches, we believe the heavy lifting of building the platform is complete. Our focus in 2026 is squarely on execution, throughput, and achieving sustained profitability".

Steven added: "Our infrastructure is now built for scale. We ended 2025 with a total liquidity position of over $9.3 million, providing us the runway needed to reach our goal of initial operational cash-flow positivity in the second half of 2026".

Conference Call & Materials

Investors, analysts, and media are invited to register in advance for the live webcast, today, March 26, 2026, at 4:30pm ET.

Live Link: [Worksport FY 2025 Earnings Call Link]

The earnings call transcript, deck, and audio reply from the conference call will be available on the Worksport website https://investors.worksport.com/#reports after the call.

Stay tuned for more information and join our mailing list to stay up to date with the latest: Join Worksport's Newsletter

Worksport FY 2025 Report: Balance Sheet & Income Statement

Below is a summary excerpt from the Financial Statements section of 'Worksport 10-K, March 26, 2026' covering the fiscal year ending December 31, 2025. Investors are encouraged to review the complete 10-K filing and the accompanying Prepared Remarks, both linked above, for full context and analysis.

Worksport Ltd.
Consolidated Balance Sheets
December 31, 2025 and 2024

2025

2024

ASSETS

Current assets

Cash and cash equivalents

$

5,945,894

$

4,883,099

Accounts receivable, net

503,971

42,589

Other receivable

278,027

169,728

Inventories, net (Note 3)

9,530,671

5,190,054

Prepaid expenses and deposits (Note 6)

530,861

192,192

Total Current assets

16,789,424

10,477,662

Investment (Note 11)

67,033

66,308

Property and equipment, net (Note 4)

12,688,488

13,644,226

Operating lease right-of-use assets (Note 11)

272,598

595,415

Intangible assets, net (Note 5)

896,531

953,049

Total assets

$

30,714,074

$

25,736,660

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities

Accounts payable

$

3,107,085

$

1,526,630

Accrued liabilities and other

1,400,730

800,283

Accrued compensation

420,210

377,112

Long-term debt, current portion (Note 12)

1,686,809

222,992

Lease liability, current portion (Note 11)

113,012

246,535

Total current liabilities

6,727,846

3,173,552

Lease liability, excluding current portion (Note 11)

159,526

368,472

Long-term debt, excluding current portion (Note 12)

950,481

4,781,005

Total liabilities

7,837,853

8,323,029

Shareholders' equity

Series A, B and Series C Preferred Stock, $0.001 par value, 10,000,000 shares authorized, 100 Series A, 0 Series B, and 427,812 Series C (for 2025) issued and outstanding, respectively (Note 7)

428

-

Series A, B and Series C Preferred Stock, $0.001 par value, 10,000,000 shares authorized, 100 Series A, 0 Series B, and 427,812 Series C (for 2025) issued and outstanding, respectively (Note 7)

428

-

Common stock, $0.001 par value, 45,000,000 shares authorized, 9,814,665 and 4,016,205 shares issued and outstanding, respectively (Note 7)

9,814

4,016

Additional paid-in capital

101,357,686

79,781,674

Share subscriptions receivable

(55,684

)

(1,577

)

Share subscriptions payable

5,446,347

2,115,064

Accumulated deficit

(83,873,790

)

(64,476,966

)

Cumulative translation adjustment

(8,580

)

(8,580

)

Total shareholders' equity

22,876,221

17,413,631

Total liabilities and shareholders' equity

$

30,714,074

$

25,736,660

The accompanying notes form an integral part of these condensed consolidated financial statements. Please click here to download the full 10-K.

Worksport Ltd.
Consolidated Statements of Operations and Comprehensive Loss
December 31, 2025 and 2024

2025

2024

Net sales

$

16,101,738

$

8,484,379

Cost of sales

11,626,831

7,578,729

Gross profit

4,474,907

905,650

Operating expenses

Research and development

1,538,923

2,289,940

General and administrative

14,806,326

11,709,925

Sales and marketing

6,947,671

2,386,504

Gain on foreign exchange

(4,587

)

(14,885

)

Total operating expenses

23,288,333

16,371,484

Loss from operations

(18,813,426

)

(15,465,834

)

Other income (expense)

Interest expense

(592,755

)

(726,095

)

Other

53,884

28,140

Total other income (expense)

(538,871

)

(697,955

)

Net loss

(19,352,297

)

(16,163,789

)

Loss per share (basic and diluted) (Note 13)

$

(3.16

)

$

(5.84

)

Weighted average number of shares (basic and diluted)

6,143,122

2,768,732

The accompanying notes form an integral part of these condensed consolidated financial statements. Please click here to download the full 10-Q.

The link below will take you to the Worksport Investor Relations Website. After 4:30pm ET, you may download the accompanying earnings call prepared remark and deck there; investors are highly encouraged to review this material:

FY 2025- Earnings Call Prepared Remarks - Download Here

Contacts

Investor Relations, Worksport Ltd. T: 1 (888) 554-8789-128

W: investors.worksport.com W: www.worksport.com E: [email protected]

Connect with Worksport Chief Executive Officer, Steven Rossi

Steven Rossi X (Twitter)
Steven Rossi LinkedIn

About Worksport

Worksport Ltd. (Nasdaq:WKSP), through its subsidiaries, designs, develops, manufactures, and owns the intellectual property on a variety of tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions. Worksport has an active partnership with Hyundai for the SOLIS Solar cover. Additionally, Worksport's hard-folding cover, designed and manufactured in-house, is compatible with all major truck models and is gaining traction with newer truck makers including the electric vehicle (EV) sector. Worksport seeks to capitalize on the growing shift of consumer mindsets towards clean energy integrations with its proprietary solar solutions, mobile energy storage systems (ESS), and Cold-Climate Heat Pump (CCHP) technology. Terravis Energy's website is terravisenergy.com.

Connect with Worksport

Please follow the Company's social media accounts on X (previously Twitter), Facebook,

LinkedIn, YouTube, and Instagram, the links of which are links to external third-party websites, as well as sign up for the Company's newsletters at investors.worksport.com.

Social Media Disclaimer

The Company does not endorse, ensure the accuracy of, or accept any responsibility for any content on these third-party websites other than content published by the Company. Investors and others should note that the Company announces material financial information to our investors using our investor relations website, press releases, Securities and Exchange Commission ("SEC") filings, and public conference calls and webcasts. The Company also uses social media to announce Company news and other information. The Company encourages investors, the media, and others to review the information the Company publishes on social media. The Company does not selectively disclose material non-public information on social media. If there is any significant financial information, the Company will release it broadly to the public through a press release or SEC filing prior to publishing it on social media.

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "scheduled," "expect," "future," "intend," "plan," "project," "envisioned," "should," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. These statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial situation may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) supply chain delays; (ii) acceptance of our products by consumers; (iii) delays in or nonacceptance by third parties to sell our products; and (iv) competition from other producers of similar products. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the SEC, including, without limitation, our latest Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances.

SOURCE: Worksport Ltd.